Funding: New Awards
Thomas H. Davis
Associate Professor
Cancer Control
- Janssen Pharmaceuticals
A randomized controlled study of YONDELIS (Trabectidin) or dacarbazine for the treatment of advanced liposarcoma or leiomyosarcoma - Boehringer Ingelheim
LUX-Head & Neck 2: A randomised, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with Stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma
Marc Ernstoff
Professor
Immunology and Cancer Immunotherapy
- Prometheus Laboratories Incorporated
A multi-center study of high dose aldesleukin (Interleukin-2)+ vemurafenib therapy in patients with BRAFV600 mutation positive metastatic melanoma - Bristol Myers Squibb
A randomized, open-label, Phase 3 study of Bms-936558 vs. everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
Peter Kaufman
Associate Professor
Molecular Therapeutics
- Nektar
The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 open-label, randomized, multicenter study of NKTR-102 versus treatment of physician`s choice (TPC) in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
J Marc Pipas
Associate Professor
Molecular Therapeutics
- Taiho
Randomized, double-blind, Phase 3 study of TAS-102 plus best supportive care (BSC)versus placebo plus BSC in patients with metastatic colorectal cancer refractory to standard chemotherapies
James R. Rigas
Associate Professor
Molecular Therapeutics
- Bristol Myers Squibb
Randomized, multicenter, double-blind, Phase 3 trial comparing the efficacy of Ipilimumab in addition to paclitaxel and carboplatin versus placebo in addition to paclitaxel and carboplatin in subjects with Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC)
Gary N. Schwartz
Associate Professor
Molecular Therapeutics
PI/Dept Funding
Tumor Specific Plasma DNA in Breast Cancer
- PI/Dept Funding
Patient-derived breast cancer xenografts - Merck and Company
A Phase 2 randomized trial of the combination of ridaforolimus and exemestane, compared to ridaforolimus, dalotuzumab and exemestane in high proliferation, estrogen receptor positive breast cancer patients
